Transaction covers Davanat, which is being developed for colorectal cancer.

Pro-Pharmaceuticals says Perceptive Imagineering will be representing the company as it brings the colorectal cancer therapy Davanat to several Central and South American Markets. Starting in Colombia, Perceptive will conduct registration, marketing, sales, and support for Davanat licensing and distribution.

Next steps are to finalize an export license and to select an established partner for distribution. The company will also focus on getting Davanat approved in Columbia to treat colorectal cancer along with 5-FU chemotherapy.

Davanat is a polymer of the carbohydrates mannose and glucose that interacts with lectins on the cell surface by targeting receptors that are over-xpressed in cancer cells. A review of Phase I and Phase II trial data showed that Davanat did not produce adverse side effects in conjunction with chemotherapy, and it reduced the incidence of mucositis, according to the company.ADNFCR-2184-ID-19145707-ADNFCR

“The collaboration with Perceptive is another deliberate step in our plan to commercialize Davanat on a regional basis,” says Theodore Zucconi, Ph.D., CEO of Pro-Pharmaceuticals. “We continue to pursue partnerships with international distributors as well as with several large international pharmaceutical companies who have established distribution and infrastructure outside the U.S. Perceptive is an experienced partner that will enable us to penetrate major markets in South and Central America.”

Related Articles
Pro-Pharmaceuticals Works with Chemwerth to Scale Up Davanat (Feb. 20, 2007)
Pro-Pharmaceuticals and Digna to Enhance Hep C Therapeutics (Feb. 30, 2007)
Pro-Pharmaceuticals Inks Repositioning Deal with Brigham and Women’s Hospital (Dec. 6, 2007)

Previous articleDuke University to Use WaferGen’s Real-Time PCR System to Validate Cancer SNPs
Next articleCerRx Obtains IP Rights to Cancer Treatment from NIH, St. John’s, CHLA